MMP-9 (-1562 C:T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 93-98

  Rahimi, Zohreh ^a,b   Rahimi, Ziba ^a   Shahsavandi, Maria Omidi ^a   Bidoki, Kazem ^a   Rezaei, Mansour ^b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

early onset pre eclampsia; MMP 9 polymorphism; severe pre eclampsia; western Iran

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 5 LEIDEN; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; GELATINASE B; MALONALDEHYDE; THYMINE; TRIACYLGLYCEROL;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MMP9 GENE; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY; RISK ASSESSMENT;

ADULT; ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 9; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; YOUNG ADULT;

EID: 84873436298     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.95     Document Type: Article

References (22)

1. Coolman M, de Maat M, Van Heerde WL et al. Matrix metalloproteinase-9 gene-1562C/T polymorphism mitigates pre-eclampsia. Placenta 28, 709-713 (2007).
2. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin. Biochem. 41, 875-880 (2008).
3. Bahrehmand F, Vaisi-Raygani A, Kiani A et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 level and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus 21, 616-624 (2012).
4. Lim KH, Zhou Y, Janatpour M et al. Human Cytotrophoblast differentiation/invasion is abnormal in preeclampsia. Am. J. Pathol. 151, 1809-1818 (1997).
5. Palei AC, Sandrim VC, Duarte G et al. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin. Chim. Acta 411, 874-877 (2010).
6. Fraser R, Walker JJ, Ekbote UV, Martin KL, McShane P, Orsi NM. Interleukin-4-590 (CT), toll-like receptor-2 +12258 (GA) and matrix metalloproteinase-9-1562 (CT) polymorphisms in pre-eclampsia. BJOG 115, 1052-1056 (2008).
7. Malek-Khosravi Sh, Rahimi Z, Rahimi Z, Jalilvand F, Parsian A. Thrombophilic mutations and susceptibility to preeclampsia in Western Iran. J. Thromb. Thrombolysis 33, 109-115 (2012).
8. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 200(5), E1-E7 (2009).
9. Rahimi Z, Ahmadian Z, Akramipour R, Vaisi-Raygani A, Rahimi Z, Parsian A. Thymidylate synthase and methionine synthase polymorphisms are not associated with susceptibility to childhood acute lymphoblastic leukemia in Kurdish population from western Iran. Mol. Biol. Rep. 39, 2195-2200 (2012).
10. Agarwal R. Rapid fluorimetric-liquid chromatographic determination of malodialdehyde in biological samples. J. Chromatogr. B 775, 121-126 (2002).
11. Rahimi Z, Rahimi Z, Mozafari H, Parsian A. Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism. J. Renin Angiotensin Aldosterone Syst. doi:10.1177/1470320312448950 (2012) (Epub ahead of print).
12. Ahmadi R, Rahimi Z, Vaisi-Raygani A, Kiani A, Jalilian N, Rahimi, Z. Apolipoprotein E genotypes, lipid peroxidation and antioxidant status among mild and severe preeclamptic women from western Iran: protective role of apolipoprotein e2 allele in severe preeclampsia. Hypertens. Pregnancy 31(4), 405-418 (2012).
13. Gremlich S, Nguyen D, Reymondin D et al. Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk. J. Reprod. Immunol. 74, 143-151 (2007).
14. Rybakowski JK. Matrix metalloproteinase-9 (MMP9)-a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc. Psychiatry Neurol. 2009, 904836 (2009).
15. Galewska Z, Bankowski E, Romanowicz L, Jaworski S. Pre-eclampsia (EPH-gestosis)-induced decrease of MMP-s content in the umbilical cord artery. Clin. Chim. Acta 335, 109-115 (2003).
16. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Gelatinase matrix metalloproteinase (MMP)-2 and MMP-9 of the umbilical cord blood in preeclampsia. Clin. Chem. Lab. Med. 46, 517-522 (2008).
17. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Matrix metalloproteinases, MMP-7 and MMP-26, in plasma and serum of control and preeclamptic umbilical cord blood. Eur. J. Obstet. Gynecol. Reprod. Biol. 150, 152-156 (2010).
18. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE. Interethnic differences in the distribution of matrix metalloproteinase genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell. Biol. 29, 649-655 (2010).
19. Metzger IF, Luizon MR, Lacchini R, Tanus-Santos JE. Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol. 31, 504-510 (2012).
20. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA, Tanus-Santos JE. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin. Chem. Lab. Med. 46(1), 57-63 (2008).
21. Montagnana M, Lippi G, Albiero A et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J. Clin. Lab. Anal. 23, 88-92 (2009).
22. Palei ACT, Sandrim VC, Amaral LM et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive disorders of pregnancy. Pharmacogenomics J. 12(6) 489-98 (2011).